Nanoparticle-assisted combination therapies for effective cancer treatment.
暂无分享,去创建一个
[1] Gigi N. C. Chiu,et al. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment , 2010, Anti-cancer drugs.
[2] T. Park,et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. , 2010, Biomaterials.
[3] Chun-Ming Huang,et al. Development of nanoparticles for antimicrobial drug delivery. , 2010, Current medicinal chemistry.
[4] Liangfang Zhang,et al. Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery. , 2010, ACS nano.
[5] Min Zhang,et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. , 2009, Small.
[6] Li Tang,et al. Controlled formulation of doxorubicin-polylactide nanoconjugates for cancer drug delivery , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[7] María J. Vicent,et al. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. , 2009, Advanced drug delivery reviews.
[8] S. Gong,et al. Doxorubicin conjugated gold nanoparticles as water-soluble and pH-responsive anticancer drug nanocarriers , 2009 .
[9] Zheng-Rong Lu,et al. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. , 2009, Biomaterials.
[10] Liangfang Zhang,et al. Therapeutic nanoparticles to combat cancer drug resistance. , 2009, Current drug metabolism.
[11] L. Mayer,et al. Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo , 2009, Molecular Cancer Therapeutics.
[12] K. Ulbrich,et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. , 2009, Biomaterials.
[13] Xiangrong Song,et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[14] N. K. Jain,et al. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics , 2009, Journal of microencapsulation.
[15] S. Ganta,et al. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. , 2009, Molecular pharmaceutics.
[16] Jianjun Cheng,et al. Ring-opening polymerization-mediated controlled formulation of polylactide-drug nanoparticles. , 2009, Journal of the American Chemical Society.
[17] K. Gelmon,et al. Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.
[18] Dar-Bin Shieh,et al. Targeted Paclitaxel by conjugation to iron oxide and gold nanoparticles. , 2009, Journal of the American Chemical Society.
[19] A. Wu,et al. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. , 2008, Protein engineering, design & selection : PEDS.
[20] Lawrence Mayer,et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. , 2009, Leukemia research.
[21] Susan E. Abbatiello,et al. Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.
[22] Stanislaus S. Wong,et al. Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. , 2008, Journal of the American Chemical Society.
[23] Ze Lu,et al. Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer , 2008, Journal of Pharmacology and Experimental Therapeutics.
[24] T. Minko,et al. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. , 2008, Nanomedicine.
[25] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[26] Jianjun Cheng,et al. Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles. , 2008, Angewandte Chemie.
[27] L. Zhang,et al. Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.
[28] D. Lim,et al. Glyconanobiotics: Novel carbohydrated nanoparticle antibiotics for MRSA and Bacillus anthracis. , 2008, Bioorganic & medicinal chemistry.
[29] N. K. Jain,et al. Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. , 2008, Journal of drug targeting.
[30] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[31] G. Kwon,et al. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[32] Omid C Farokhzad,et al. Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.
[33] E. Zubarev,et al. Paclitaxel-functionalized gold nanoparticles. , 2007, Journal of the American Chemical Society.
[34] J. Au,et al. Tumor Priming Enhances Delivery and Efficacy of Nanomedicines , 2007, Journal of Pharmacology and Experimental Therapeutics.
[35] H. Dai,et al. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. , 2007, Journal of the American Chemical Society.
[36] L. Mayer,et al. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. , 2006, Oncology research.
[37] Xiaogang Pan,et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[38] Ho Sup Yoon,et al. Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer , 2006, Nature materials.
[39] M. Bally,et al. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.
[40] P. Couvreur,et al. Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.
[41] J. Richie,et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[42] F. Journé,et al. Sequence-dependent synergistic effects of ibandronate in combination with antiestrogens on growth inhibition of estrogen receptor-positive breast cancer cells , 2006 .
[43] P. Ellis,et al. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Shiladitya Sengupta,et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.
[45] M. Paul,et al. 6-Mercaptopurine and Daunorubicin Double Drug Liposomes—Preparation, Drug-Drug Interaction and Characterization , 2005, Journal of liposome research.
[46] L. Brannon-Peppas,et al. Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.
[47] Jinha M. Park,et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. , 2004, Protein engineering, design & selection : PEDS.
[48] Jeffrey S. Johnston,et al. Synergy Between 3′Azido-3′deoxythymidine and Paclitaxel in Human Pharynx FaDu Cells , 2003, Pharmaceutical Research.
[49] A. Katz,et al. Maladaptive Growth in the Failing Heart: The Cardiomyopathy of Overload , 2002, Cardiovascular Drugs and Therapy.
[50] Vincristine liposomal--INEX: lipid-encapsulated vincristine, onco TCS, transmembrane carrier system--vincristine, vincacine, vincristine sulfate liposomes for injection, VSLI. , 2004, Drugs in R&D.
[51] M. Gilbert,et al. An Open Label Trial of Sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis , 2004, Journal of Neuro-Oncology.
[52] Kenneth K. Chan,et al. Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome) , 2004, Investigational New Drugs.
[53] D. Hossfeld,et al. Effects of verapamil on the pharmacokinetics and metabolism of epirubicin , 2004, Cancer Chemotherapy and Pharmacology.
[54] Theresa M Allen,et al. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.
[55] M. Gottesman. Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.
[56] D. Montaudon,et al. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants , 2001, British Journal of Cancer.
[57] U. Nielsen,et al. Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[58] J. Blay,et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. , 2001, European journal of cancer.
[59] Y. Rustum,et al. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. , 2000, Cancer research.
[60] D. Pode,et al. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer , 2000, Anti-cancer drugs.
[61] T. Lawrence,et al. Interaction between gemcitabine and mitomycin-C in vitro , 2000, Cancer Chemotherapy and Pharmacology.
[62] P Couvreur,et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. , 2000, Biomaterials.
[63] L. Recht,et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[64] F. Kratz,et al. Drug-polymer conjugates containing acid-cleavable bonds. , 1999, Critical reviews in therapeutic drug carrier systems.
[65] M A Fischl,et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[67] B. Tromberg,et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. , 1996, Cancer research.
[68] J. Rousseau,et al. PEG‐coated Poly(lactic acid) Nanoparticles for the Delivery of Hexadecafluoro Zinc Phthalocyanine to EMT‐6 Mouse Mammary Tumours , 1995, The Journal of pharmacy and pharmacology.
[69] D. Bazile,et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.
[70] M. Hashida,et al. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. , 1995, Critical reviews in oncology/hematology.
[71] David Putnam,et al. Polymer conjugates with anticancer activity , 1995 .
[72] R. Dorr,et al. The effect of anticancer drug sequence in experimental combination chemotherapy. , 1993, Cancer investigation.
[73] T. Miller,et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. , 1991, Journal of the National Cancer Institute.
[74] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[75] F. Szoka,et al. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. , 1979, Biochimica et biophysica acta.
[76] D. J. Adamson,et al. Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. , 1975, Cancer research.
[77] A. Bangham,et al. Single bilayer liposomes. , 1971, Biochimica et biophysica acta.
[78] A. Bangham,et al. Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.